Non-Invasive Cancer Diagnostics
Market - Regional Analysis
On the basis of region, the
global Non-Invasive
Cancer Diagnostics Market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant
position in the non-invasive diagnostics market, owing to increasing incidence
of cancer, increasing technological advancement, better reimbursement scenario,
and governmental initiatives for screening of cancer in early stages. For instance,
the American Cancer Society Guidelines for the early detection of cancer offers
various screening plans at different ages. For example, the guidelines suggest
that women between the age of 40 and 44 must screen for breast cancer annually.
Moreover market players in the APAC region are involved in partnerships and
agreements to enhance the market growth in cancer diagnostics. For instance, In
April 2019, Halifax signed an exclusive distribution agreement with Genecast to
make Immunoscore assay available in China.
Non-Invasive Cancer Diagnostics
Market – Competitive Landscape
Some of the key players operating
in the global non-invasive cancer diagnostics market include Roche Diagnostics,
Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular,
IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte
Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.
Increasing product launches as a
part of organic strategies to rule the market is also the key factor
contributing to the non-invasive cancer diagnostics market growth. For
instance, in March 2019, NeoGenomics Laboratories Inc. announced the launch of
Ventana PD-L1 (SP142) Assay for tumor tissue testing in patients with a triple
negative subtype of breast cancer. The test is approved by the US FDA for
patients who might respond to TECENTRIQ, an immune checkpoint inhibitor in
combination with chemotherapy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1651
Non-invasive cancer diagnostics
are procedures used for the identification of cancer without incision in the
body. Detection and treatment of cancer at early stages are important for
long-term survival. Non-invasive cancer detection method is found to be an
increasing choice of interest, owing to its painless or minimal pain method of
diagnostic coupled with more accurate results. Molecular based diagnostic
methods are expected to increase during the forecast period due to launches of
new biomarker based detection methods. Moreover, factors like increasing
incidence of cancer, increasing cancer screening rate, government initiatives,
and emerging technologies such as next generation sequencing are expected to
drive the market during the forecast period.
According to Cancer Research UK,
currently no diagnostic tests are 100% sensitive in general practice. This suggests
the unmet demand for novel diagnostic assay with more efficiency. The
efficiency of molecular diagnostics for screening of blood and tissue sample
for cancer detection fuels the research and development of biomarker based
molecular diagnostic method, which can detect abnormalities in their early
developmental cycle. Moreover, according to Genome Biology article published in
2017, the current research in non-invasive cancer detection are targeting two
class of studies - the development of biomarkers for a specific cancer type and
the characterization of circulating tumor DNA (ctDNA) for general cancer
detection, without trying to predict specific cancer types. Such studies will
help manufacturers to develop better cancer detection kits for molecular based
diagnostics.
Non-Invasive Cancer Diagnostics
Market Drivers
Increasing incidence of cancer is
expected to be a major factor driving growth of non-invasive cancer diagnostics
market. Cancer is a major factor impacting the world economy. For instance, according
to the World Health Organization (WHO) 2018 Factsheet, Cancer is the second
leading cause of death globally, and is responsible for an estimated 9.6
million deaths in 2018. Globally, about 1 in 6 deaths is occurred due to
cancer.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/non-invasive-cancer-diagnostics-market-1651
Increasing rate of cancer
detection will also boost the non-invasive cancer diagnostics market growth.
According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers,
the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013,
as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmental
and non-governmental organizations are engaged in raising awareness for breast
and cervical cancer as well as conducts screening programme. The National
Institute for Health and Care Excellence (NICE) is involved in improving
diagnosis rate by revising draft guideline for early cancer detection.
Moreover, increasing cancer studies for cancer drug development will boost the
non-invasive cancer diagnostics market growth. In 2016, NCI's Center to Reduce
Cancer Health Disparities launched the National ‘Screen to Save’ Colorectal
Cancer Outreach and Screening Initiative. The initiative was aimed at
increasing colorectal cancer screening rate.
Further, in 2016, Exosome
Diagnostics, Inc. launched ExoDx Prostate (IntelliScore) test. The test uses
genetic information from urine sample to evaluate patient risk for high grade
prostate cancer.
In 2016, Laboratory Corporation
of America Holdings, launched Epi proColon, the first FDA-approved DNA based
blood test for colorectal cancer screening with FDA approval.
The inorganic strategies by
market players are continuously boosting the non-invasive cancer diagnostics
market. For instance, For instance, in November 2018, Belgian molecular
diagnostics company, Biocartis Group entered into an agreement with AstraZeneca
for development of lung cancer molecular diagnostic biomarker.
In 2017, Lonza, a
biopharmaceutical development and manufacturing company, acquired HanaBioMaed
Life Sciences OU, a company dedicated to research and development,
manufacturing and distribution of products for the exosome genome market.
Through this acquisition, company will invest to develop exosome-based
early-stage cancer screening and molecular diagnostic tests. In same year, CORE
Diagnostics partnered with CellMax Life to introduce CellMax’s genetic cancer
risk test and ctDNA-based liquid biopsy throughout India.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1651
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent Market
Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
